Galapagos (GLPG) to Release Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is expected to announce its earnings results after the market closes on Wednesday, April 23rd. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $72.22 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Galapagos Price Performance

NASDAQ:GLPG opened at $24.66 on Monday. The firm has a 50 day simple moving average of $25.37 and a 200-day simple moving average of $26.30. Galapagos has a 1-year low of $22.36 and a 1-year high of $31.23.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $31.00 to $22.00 in a report on Friday, February 14th. Barclays restated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, TD Cowen cut shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Four investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $25.33.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.